Article: FDA Approves New Drug for Severe Pain

[Guest guest]

Source: http://www.intelihealth.com/IH/ihtIH/EMIHC267/333/21291/405720.html?d=dmtICNNews

Advertisement

FDA Approves New Drug for Severe Pain

December 29, 2004

WASHINGTON (AP) -- The government approved a drug Tuesday that offers a new way of fighting severe pain -- an option for patients who no longer benefit from morphine and other traditional pain medications.

It's the first in a new class of drugs that selectively blocks the nerve channels responsible for transmitting pain signals. It will be marketed as Prialt and should be available by the end of January.

"When you've taken all the kinds of pain medication that there is and you still have pain, that is a very frightening situation," said Dr. Lars Ekman, president of research and development for the drug's Ireland-based manufacturer, Elan. "When you have that kind of pain, there is nowhere to go."

The drug is part of a new class known as N-type calcium channel blockers. It is known chemically as ziconotide.

Morphine is the standard treatment for severe pain from cancer, AIDS, amputations and other significant illnesses, but its effects eventually wear off and the dosage must be increased. At some point, many patients switch from taking medication by mouth or by injection to a microinfusion pump implanted under the skin that delivers drugs directly into the fluid surrounding the spinal cord.

Ekman said about 35,000 to 50,000 Americans have these pumps now. The Food and Drug Administration approved Prialt for patients who are already using these pumps but not getting effective relief from them or who cannot tolerate the available treatments.

This is the first new drug in 20 years to treat pain using such a pump.

Prialt has been studied in patients with cancer, AIDS and other chronic pain, such as back pain. More than 1,200 patients took part in three clinical trials.

There are side effects, and the FDA was including a "black box" warning -- the government's strongest warning short of a ban. Side effects may include dizziness, drowsiness and altered mental status, with patients confused at times.

Despite the side effects, the drug was approved because there are no other options for these patients and the benefits outweighed the risks, said Dr. Meyer, director of the FDA's Office of Drug Evaluation II.

"Because this is such an important patient population where they have such pain and they have so few options we felt this drug does offer some real gains," he said.

Patients with a history of psychoses should not receive it, and all others should be monitored for signs of cognitive impairment, he said.

The idea for the drug came from a snail called the Conus magus that lives in the South Pacific, which paralyzes its victims with venom after capturing them, the company said. Researchers set out learning how to develop a drug based on this venom and eventually copied the amino acid sequence.

Elan would not say how much it plans to charge for the drug.

Copyright 2004 The Associated Press. All rights reserved.

More News

•

Top News

•

General Health

•

This Week In Health

•

Addiction

•

Allergy

•

Alzheimer's

•

Asthma

•

Arthritis

•

Babies

•

Breast Cancer

•

Cancer

•

Caregiving

•

Cervical Cancer

•

Children's Health

•

Cholesterol

•

Complementary & Alternative Medicine

•

Dental / Oral Health

•

Depression

•

Diabetes

•

Ear, Nose And Throat

•

Eyes

•

Family Health

•

Fitness

•

Headache

•

Heart Health

•

HIV / AIDS

•

Infectious Diseases

•

Lung Cancer

•

Medications

•

Men's Health

•

Mental Health

•

Nutrition News

•

Multiple Sclerosis

•

Nutrition Guide

•

Parkinson's

•

Pregnancy

•

Prevention

•

Prostate Cancer

•

Senior Health

•

Sexual / Reproductive Health

•

Sleep

•

Smoking Cessation

•

STDs

•

Stress Reduction

•

Stroke

•

Weight Management

•

Today In Health History

•

Women's Health

•

Workplace Health

Printer-friendly format

Help | About Us | Privacy Policy | Editorial Policy | Advertising Policy | How To Advertise | Contact Us | RegisterChange Profile

© 1996-2004 Aetna InteliHealth Inc. All rights reserved. All information is intended for your general knowledge only and is not a substitute for medical advice or treatment for specific medical conditions. You should seek prompt medical care for any specific health issues and consult your physician before starting a new fitness regimen. Use of this online service is subject to the disclaimer and the terms and conditions. External Web site links provided on this site are meant for convenience and for informational purposes only; they do not constitute an endorsement. These external links open in a different window. Aetna InteliHealth has been awarded Health Web site accreditation by URAC and is a founding member of Hi-Ethics. We also subscribe to the HONcode principles of the Health On the Net Foundation. "InteliHealth" and "The Trusted Source" are trademarks of Aetna InteliHealth Inc.

•

Complementary & Alternative Medicine

•

Fitness

•

Nutrition

•

Weight Management

•

Workplace Health

•

Children's Health

•

Men's Health

•

Seniors' Health

•

Women's Health

•

More

•

Medical Dictionary

•

Health A-Z

•

Drug Resource Center

•

More

•

Addiction

•

Allergy

•

Alzheimer's Disease

•

Anemia

•

Arthritis

•

Asthma

•

Breast Cancer

•

Cancer

•

Cholesterol

•

Chronic Obstructive Pulmonary Disease

•

Chronic Pain

•

Dementia

•

Depression

•

Diabetes

•

Digestive

•

Digestive-Tract Cancer

•

Ear, Nose And Throat Disorders

•

Epilepsy

•

Eyes

•

Feet

•

Glaucoma

•

HIV/AIDS

•

Hair Loss

•

Headache

•

Heart And Circulatory

•

High Blood Pressure

•

Impotence

•

Infertility

•

Kidney Disease

•

Low Back Pain

•

Lyme Disease

•

Macular Degeneration

•

Memory Loss

•

Mental Health

•

Multiple Sclerosis

•

Osteoarthritis

•

Pregnancy

•

Prostate Cancer

•

Rheumatoid Arthritis

•

Sexual And Reproductive Health

•

Sexually Transmitted Diseases

•

Skin Cancer

•

Sleep

•

Stress

•

Stroke

•

Weight Management